Epigenetics Market Forecasts to 2028 – Global Analysis By Product (Kits & Reagents, Enzymes, Instruments and Accessories, Software and Other Products), Technique (Next-generation sequencing (NGS), PCR & qPCR, Mass Spectrometry, Sonication and Other Techni

Epigenetics Market Forecasts to 2028 – Global Analysis By Product (Kits & Reagents, Enzymes, Instruments and Accessories, Software and Other Products), Technique (Next-generation sequencing (NGS), PCR & qPCR, Mass Spectrometry, Sonication and Other Techniques), Technology, Application, End User and By Geography

According to Stratistics MRC, the Global Epigenetics Market is accounted for $1.7 billion in 2022 and is expected to reach $5.10 billion by 2028 growing at a CAGR of 20.1% during the forecast period. Epigenetics refers to a stream of genetics that involves the study of physiological and cellular trait variations initiated by external or ecological aspects, which turn genes on and off and affect the cellular ability to read the genes without being impacted by changes in genotype. It results in changes in the phenotype of an organism rather than the genotype, where the underlying RNA or DNA sequence remains unchanged. Epigenetic alterations are vital for development as they are dynamic and change as per the surrounding environment's stimuli.

According to WHO, the worldwide population of people aged 65 and up is estimated to grow from 1 billion in the year 2019 to approximately 2.1 billion in 2050.

Market Dynamics

Driver

Cancer is becoming more prevalent

The increasing number of epigenetic applications in cancer treatment and other illnesses is expected to drive the global epigenetics business forward. Numerous research institutes are thoroughly investigating epigenetics in order to develop necessary vaccines and drugs for abnormalities that do not currently have effective therapies assigned to them because it has been shown to be highly effective in treating specific types of cancer. Organizations such as the National Cancer Institute, Human Epigenome Consortium, and National Institute of Health have lobbied for more epigenetics investment not only for research but also for commercialization, which is expected to promote global expansion over the projected period.

Restraint

Limited applications of epigenomic data in toxicology

Toxicology has seen the limited application of epigenomic data an incomplete understanding of epigenomic variability has led to restricted knowledge on risk assessment across different tissue types and populations. This requires developing new solutions to ensure a comprehensive understanding of epigenetic mechanisms, resulting in detailed epigenomic variation mapping. A key obstacle to the application of epigenomic analysis in toxicology is the lack of identification and consensus on a normal epigenome for all tissues and cell types, which are projected to impede the fog computing market's growth.

Opportunity

Utilization in personalized pharmaceuticals

Patients are given genomic or personalized medicines after obtaining genetic data as well as associated information such as levels of RNA, proteins, and other metabolites, which are critical aspects in medical decision-making for personalized medicine. Genomic methods such as transcriptomics, finding DNA sequence variants, metabolomics, and proteomics are useful for accurate disease management and prediction. These tactics are powerful tools for bridging the gap between epigenetics and personalized medicine. Furthermore, information from a specific genome sequence, as well as the related biomarkers, is essential for personalized and genomic medicines to be identified, which is another critical reason expected to aid the expansion of the epigenetics market.

Threat

Lack of standardization

Epigenetics research involves a wide range of experimental protocols, including sample preparation, DNA extraction, bisulfite conversion and data analysis. Without standardized protocols, there can be variations in methodologies and techniques used across different laboratories and research groups. These inconsistencies can lead to difficulties in comparing and replicating results, reducing the reliability and reproducibility of findings. Standardization is crucial for the development of reliable and validated epigenetic biomarkers. Biomarkers play a critical role in disease diagnosis, prognosis, and treatment selection. Inconsistent protocols and methodologies can lead to variations in biomarker discovery and validation, making it challenging to establish robust and clinically relevant biomarkers, which becomes a threat to market growth.

Covid-19 Impact

COVID-19 has significantly impacted the epigenetics market growth due to the importance of epigenetics in COVID-19 research. Epigenetic modifications may play an important role in the beginning of corona virus illness consequences. Despite the fact that several treatment alternatives are being researched, more research is urgently required to develop a viable vaccine or safer chemotherapeutic drugs, including epigenetic treatments, to combat this viral pandemic and provide before and post-exposure COVID-19 prophylaxis. This will result in increased use of epigenetics in the discovery of COVID-19 infection therapeutics, which is projected to fuel market growth during the forecast period.

The kits & reagents segment is expected to be the largest during the forecast period

The kits & reagents segment has generated the greatest revenue share in the market, owing to the increased development of simple-to-use, low-cost, and advanced epigenetic kits and reagents. This is aided by the exponential increase in the number of epigenetic research papers conducted over the years. Antibodies, ChiP-seq kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC and 5-mC analysis kits, histones, and other kits & reagents are further subdivided. Epigenetics software tools aid in the investigation of complicated epigenetic alterations, thereby boosting market growth.

The Next-generation sequencing (NGS) segment is expected to have the highest CAGR during the forecast period

Next-generation sequencing (NGS) segment is expected to witness fastest growth and expected to have the highest CAGR in the market over the forecast period. NGS techniques can be integrated with other omics technologies, such as genomics, transcriptomics, and proteomics, to enable comprehensive multi-omics analysis. This integration allows researchers to gain a holistic view of the interplay between different layers of molecular regulation, including epigenetic modifications, and provides valuable insights into complex biological processes and disease mechanisms, which is a crucial factor fostering the expansion of the global market.

Region with largest share

The North American Epigenetics market dominated the global market, and it is anticipated that this dominance will continue over the course of the forecast period. North America, particularly the United States, has a robust research infrastructure and funding mechanisms that support epigenetics research. Renowned research institutions such as Harvard University, Massachusetts Institute of Technology (MIT), and University of California, San Francisco (UCSF) are actively involved in epigenetics studies. This focus on research and development fuels innovation and drives the growth of the market.

Region with highest CAGR

Asia Pacific is predicted to grow at the highest CAGR in this Epigenetics market over the forecast period. The Asia Pacific region has a high burden of diseases such as cancer, cardiovascular disorders, and neurological conditions. Epigenetic diagnostics offer the potential for early detection, prognosis, and personalized treatment options. As a result, there is a growing demand for epigenetic testing services and diagnostic products in the region. Companies are developing epigenetic biomarker-based tests for various diseases to cater to this demand. The combination of increasing research activities, investments from the biotechnology and pharmaceutical sectors, government support, and the rising adoption of precision medicine contribute to the development and expansion of the epigenetics market in the region.

Key players in the market

Some of the key players in Epigenetics Market include Abcam PLC, Active Motif, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Creative Biogene, Diagenode, Dovetail Genomics LLC., Eisai Co. Ltd., Element Biosciences, Inc., Epigentek Group INC., F. Hoffmann-La Roche Ltd, Hologic Inc., Illumina Inc., Merck & Co. Inc., New England Biolabs, Novartis AG, PerkinElmer, Qiagen NV, Roche Diagnostics, Thermo Fisher Scientific, Inc., ValiRx Plc. and Zymo Research Corporation.

Key Developments

In Sep 2022, PacBio introduced DNA methylation capabilities via its product line, Sequel, in the US. Introducing this feature to the Sequel systems is expected to extend the accessibility of epigenomes via HiFi sequencing developed by the company

In February 2022, Zenith Epigenetics Ltd. reported the dosing of the first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor OPDIVO and YERVOY in a National Cancer Institute (NCI), part of the National Institutes of Health

In December 2021, Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, entered a partnership with Dovetail Genomics to demonstrate the value and performance of Dovetail’s proximity ligation-based-based next-generation sequencing (NGS) library prep solutions on Element’s AVITI System

Products Covered
• Kits & Reagents
• Enzymes
• Instruments and Accessories
• Software
• Other Products

Techniques Covered
• Next-generation sequencing (NGS)
• PCR & qPCR
• Mass Spectrometry
• Sonication
• Other Techniques

Technologies Covered
• DNA Methylation
• Histone Modifications
• Acetylation
• Phosphorylation
• Large non - coding RNA
• Other Technologies

Applications Covered
• Oncology
• Non-Oncology
• Metabolic Diseases
• Immunology
• Developmental Biology
• Cardiovascular Diseases
• Other Applications

End Users Covered
• Academic
• Research Institutes
• Pharmaceutical
• Biotechnology Companies
• Hospitals
• Clinics

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities,Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements